Cerapedics Secures Vizient Supplier Agreement for PearlMatrix P-15 Bone Graft Treatment

Key Takeaways

• Cerapedics signed a supplier agreement with Vizient, the largest healthcare performance improvement company, for PearlMatrix P-15 bone graft distribution
• The partnership expands patient access to the Class III drug-device combination product for treating degenerative disc disease in the lumbar spine
• Agreement positions Cerapedics to reach Vizient’s extensive network of healthcare providers across the United States

---

Cerapedics Inc. announced on April 24, 2026, that it has entered into a strategic supplier agreement with Vizient for its PearlMatrix P-15 Peptide Enhanced Bone Graft, significantly expanding access to this innovative spine treatment across the United States.

Partnership Details

The Westminster, Colorado-based orthopedics company will now supply its Class III drug-device combination product through Vizient’s extensive healthcare network. Vizient serves as the nation’s largest provider-driven healthcare performance improvement company, connecting Cerapedics with a vast network of hospitals and healthcare systems.

PearlMatrix P-15 is specifically indicated for adult patients suffering from degenerative disc disease in the lumbar spine. The peptide-enhanced bone graft represents a significant advancement in spinal fusion technology, combining synthetic bone graft material with P-15 peptide to promote natural bone healing.

Market Impact and Implications

This supplier agreement marks a crucial milestone for Cerapedics’ commercial expansion strategy. By partnering with Vizient, the company gains access to healthcare providers nationwide, potentially accelerating adoption of PearlMatrix P-15 among spine surgeons and orthopedic specialists.

The partnership comes at a time when demand for innovative spine treatments continues to grow, driven by an aging population and increasing prevalence of degenerative disc disease. Healthcare systems are actively seeking advanced solutions that can improve patient outcomes while maintaining cost-effectiveness.

About the Technology

PearlMatrix P-15 combines anorganic bone mineral with a synthetic peptide that mimics a portion of human Type I collagen. This unique formulation is designed to enhance the body’s natural bone healing process, potentially leading to improved fusion rates and better patient outcomes in spinal procedures.

The product has undergone rigorous clinical testing and regulatory review as a Class III medical device, representing the highest level of regulatory oversight for medical devices in the United States.

---

Frequently Asked Questions

What does this partnership mean for patients needing spine surgery?

Patients will have broader access to PearlMatrix P-15 through Vizient’s network of healthcare providers, potentially improving treatment options for degenerative disc disease in more locations across the country.

When will PearlMatrix P-15 be available through Vizient providers?

The supplier agreement is now in effect as of April 2026, though individual healthcare systems within Vizient’s network will determine their own adoption timelines based on their specific procurement processes.

How does PearlMatrix P-15 differ from traditional bone grafts?

PearlMatrix P-15 combines synthetic bone mineral with P-15 peptide technology that mimics human collagen, designed to enhance natural bone healing compared to traditional bone graft materials used in spinal fusion procedures.